Arvinas (NASDAQ:ARVN) Research Coverage Started at Stephens

Stephens started coverage on shares of Arvinas (NASDAQ:ARVN) in a research report sent to investors on Monday morning, Marketbeat reports. The brokerage issued an overweight rating and a $55.00 price objective on the stock.

ARVN has been the subject of several other research reports. Wedbush restated an “outperform” rating and set a $57.00 price target on shares of Arvinas in a research report on Tuesday, July 30th. Barclays reduced their price objective on shares of Arvinas from $60.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $87.00 price target on shares of Arvinas in a research report on Thursday, October 31st. Finally, Oppenheimer reduced their price target on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.08.

Arvinas Trading Up 4.9 %

NASDAQ ARVN opened at $22.69 on Monday. The company’s fifty day simple moving average is $25.62 and its 200-day simple moving average is $27.06. Arvinas has a 52 week low of $20.28 and a 52 week high of $53.08. The stock has a market cap of $1.56 billion, a P/E ratio of -4.86 and a beta of 1.96.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.20. The firm had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. The company’s revenue for the quarter was up 196.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.18) earnings per share. On average, research analysts expect that Arvinas will post -3.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Arvinas by 29.9% in the 1st quarter. Vanguard Group Inc. now owns 6,299,556 shares of the company’s stock valued at $260,046,000 after buying an additional 1,448,166 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Arvinas by 137.2% during the 2nd quarter. SG Americas Securities LLC now owns 86,096 shares of the company’s stock worth $2,292,000 after purchasing an additional 49,799 shares in the last quarter. Candriam S.C.A. grew its holdings in shares of Arvinas by 32.0% during the 2nd quarter. Candriam S.C.A. now owns 610,458 shares of the company’s stock worth $16,250,000 after purchasing an additional 147,904 shares in the last quarter. Magnetar Financial LLC grew its holdings in shares of Arvinas by 112.7% during the 2nd quarter. Magnetar Financial LLC now owns 41,992 shares of the company’s stock worth $1,118,000 after purchasing an additional 22,245 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Arvinas by 32.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 235,096 shares of the company’s stock worth $6,258,000 after purchasing an additional 57,835 shares in the last quarter. 95.19% of the stock is owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.